Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Agomelatine (1) ·
Amoxapine (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Levothyroxine (1) ·
Liothyronine (T3, triiodothyronine sodium) (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Thyroid (desiccated) (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1)
None (1) ·
Anafranil (1) ·
Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Cytomel (oral), Triostat (IV) (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Synthroid, Levoxyl, Tirosint, Unithroid, Euthyrox (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
None (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00000032-QINU`"' Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic'"`UNIQ--ref-00000033-QINU`"'. (1)
None (18) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) ·
'"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) ·
'"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"' (1)
None (18) ·
1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) ·
25 mg (1) ·
30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine (1) ·
Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading (1)
None (18) ·
15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg) (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) ·
5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat) (1)
None (17) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Hours (faster than T4); peak biologic activity 24-48 hours (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
TSH normalization 4-8 weeks (1) ·
TSH normalization 4-8 weeks; symptomatic improvement weeks to months (1)
None (17) ·
T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"' (1) ·
~1 day (much shorter than T4's ~7 days)'"`UNIQ--ref-0000149D-QINU`"' (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1)
None (17) ·
40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' (1) ·
~50% (highly variable) (1) ·
~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' (1)
None (17) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 22 results in range #1 to #22.


